Resverlogix (RVX) Stock Chart & Stock Price History C$0.06 -0.02 (-26.67%) (As of 11/4/2024 ET) Add Compare Share Share Chart Stock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades Resverlogix Stock Price Performance5 Day Performance-15.38%1 Month Performance0.00%3 Month Performance0.00%6 Month Performance-8.33%Year-To-Date Performance-21.43%1 Year Performance-21.43% Receive RVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Resverlogix and its competitors with MarketBeat's FREE daily newsletter Email Address Ad TradingTips10 EV Stocks to Buy Right NowEV stocks are red hot. We’ve found TEN that we think will produce big wins for early investors. There’s no charge to view this report, so I urge everyone to check out the 10 stocks we’ve found as soon as possible.Click here to view all 10 stocks right away. RVX Stock Chart for Tuesday, November, 5, 2024 RVX Chart by TradingView Resverlogix Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization11/04/2024N/AC$0.06C$0.06C$0.0670,073 shsC$15.23 million11/01/2024C$0.07C$0.07C$0.07C$0.071,000 shsC$18.00 million10/31/2024C$0.07C$0.07C$0.07C$0.071,000 shsC$18.00 million10/30/2024C$0.07C$0.07C$0.07C$0.071,000 shsC$18.00 million10/29/2024C$0.07C$0.07C$0.07C$0.071,000 shsC$18.00 million10/28/2024C$0.07C$0.07-7.14%C$0.07C$0.0643,000 shsC$18.00 million Get the Latest News and Ratings for RVX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Resverlogix and its competitors with MarketBeat's FREE daily newsletter. 10/25/2024C$0.07C$0.07C$0.07C$0.071,000 shsC$18.00 million10/24/2024C$0.07C$0.07C$0.07C$0.073,650 shsC$18.00 million10/23/2024C$0.06C$0.07+8.33%C$0.07C$0.0726,050 shsC$18.00 million10/22/2024C$0.06C$0.06C$0.06C$0.0618,000 shsC$16.62 million10/21/2024C$0.07C$0.06-7.69%C$0.06C$0.0618,000 shsC$16.62 million10/18/2024C$0.06C$0.07+8.33%C$0.07C$0.0614,900 shsC$18.00 million10/17/2024C$0.06C$0.06C$0.06C$0.062,500 shsC$16.62 million10/16/2024C$0.06C$0.06C$0.06C$0.0636,550 shsC$16.62 million10/15/2024C$0.07C$0.06-7.69%C$0.06C$0.06236,385 shsC$16.62 million10/14/2024C$0.07C$0.07-7.14%C$0.07C$0.06322,803 shsC$18.00 million10/11/2024C$0.07C$0.07C$0.07C$0.06322,803 shsC$18.00 million10/10/2024C$0.07C$0.07C$0.07C$0.0670,900 shsC$18.00 million10/09/2024C$0.06C$0.07+8.33%C$0.07C$0.06221,830 shsC$18.00 million10/08/2024C$0.06C$0.06C$0.06C$0.0615,000 shsC$16.62 million10/07/2024C$0.06C$0.06+9.09%C$0.06C$0.0530,349 shsC$16.62 million10/04/2024C$0.06C$0.06C$0.06C$0.061,000 shsC$15.23 million10/03/2024C$0.06C$0.06C$0.06C$0.0612,000 shsC$15.23 million10/02/2024C$0.06C$0.06C$0.06C$0.061,000 shsC$15.23 million10/01/2024C$0.06C$0.06C$0.06C$0.052,350 shsC$15.23 million09/30/2024C$0.05C$0.06+10.00%C$0.06C$0.05332,050 shsC$15.23 million09/27/2024C$0.05C$0.05C$0.06C$0.05240,500 shsC$13.85 million09/26/2024C$0.06C$0.05-9.09%C$0.06C$0.05263,800 shsC$13.85 million09/25/2024C$0.07C$0.06-21.43%C$0.07C$0.06295,777 shsC$15.23 million09/24/2024C$0.07C$0.07+7.69%C$0.07C$0.072,000 shsC$19.39 million09/23/2024C$0.07C$0.07C$0.07C$0.072,000 shsC$18.00 million09/20/2024C$0.07C$0.07C$0.07C$0.0746,000 shsC$18.00 million09/19/2024C$0.07C$0.07C$0.07C$0.073,025 shsC$18.00 million09/18/2024C$0.07C$0.07C$0.07C$0.079,000 shsC$18.00 million09/17/2024C$0.07C$0.07C$0.07C$0.07105,000 shsC$18.00 million09/16/2024C$0.06C$0.07+8.33%C$0.07C$0.0739,179 shsC$18.00 million09/13/2024C$0.07C$0.06-11.11%C$0.07C$0.06158,360 shsC$16.62 million09/12/2024C$0.07C$0.07-3.57%C$0.07C$0.0761,000 shsC$18.70 million09/11/2024C$0.07C$0.07C$0.07C$0.0719,050 shsC$19.39 million09/10/2024C$0.07C$0.07-3.45%C$0.08C$0.0711,000 shsC$19.39 millionThe Final Frontier (Ad)And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you.09/09/2024C$0.08C$0.07-3.33%C$0.08C$0.078,275 shsC$20.08 million09/06/2024C$0.08C$0.08C$0.08C$0.0812,080 shsC$20.77 million09/05/2024C$0.08C$0.08C$0.08C$0.0844,000 shsC$20.77 million09/04/2024C$0.08C$0.08-6.25%C$0.08C$0.0858,000 shsC$20.77 million09/03/2024C$0.09C$0.08-11.11%C$0.09C$0.0849,419 shsC$22.16 million09/02/2024C$0.09C$0.09C$0.09C$0.091.03 million shsC$24.93 million08/30/2024C$0.09C$0.09C$0.09C$0.091.03 million shsC$24.93 million08/29/2024C$0.09C$0.09+5.88%C$0.10C$0.08284,755 shsC$24.93 million08/28/2024C$0.09C$0.09C$0.09C$0.0822,987 shsC$23.54 million08/27/2024C$0.09C$0.09-5.56%C$0.09C$0.0986,750 shsC$23.54 million08/26/2024C$0.09C$0.09C$0.09C$0.09479,125 shsC$24.93 million08/23/2024C$0.09C$0.09C$0.09C$0.09362,200 shsC$24.73 million08/22/2024C$0.09C$0.09C$0.09C$0.08307,699 shsC$24.73 million08/21/2024C$0.08C$0.09+12.50%C$0.09C$0.09186,000 shsC$24.73 million08/20/2024C$0.08C$0.08C$0.08C$0.0813,000 shsC$21.99 million08/19/2024C$0.08C$0.08C$0.09C$0.08172,550 shsC$21.99 million08/16/2024C$0.08C$0.08+6.67%C$0.09C$0.08276,550 shsC$21.99 million08/15/2024C$0.07C$0.08+15.38%C$0.09C$0.07326,786 shsC$20.61 million08/14/2024C$0.07C$0.07C$0.07C$0.0740,430 shsC$17.86 million08/13/2024C$0.06C$0.07+8.33%C$0.07C$0.062,001 shsC$17.86 million08/12/2024C$0.07C$0.06-7.69%C$0.06C$0.065,000 shsC$16.49 million08/09/2024C$0.06C$0.07+18.18%C$0.07C$0.05289,489 shsC$17.86 million08/08/2024C$0.06C$0.06-8.33%C$0.06C$0.065,000 shsC$15.12 million08/07/2024C$0.06C$0.06+9.09%C$0.06C$0.0613,000 shsC$16.49 million08/06/2024C$0.06C$0.06C$0.06C$0.05122,926 shsC$15.12 million08/05/2024C$0.06C$0.06C$0.06C$0.0613,000 shsC$15.12 million Related Companies Microbix Biosystems Stock Chart Helix BioPharma Stock Chart BriaCell Therapeutics Stock Chart Ceapro Stock Chart Kane Biotech Stock Chart Devonian Health Group Stock Chart Aeterna Zentaris Stock Chart Sirona Biochem Stock Chart Aptose Biosciences Stock Chart Hemostemix Stock Chart Receive RVX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Resverlogix and its competitors with MarketBeat's FREE daily newsletter. This page (TSE:RVX) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Resverlogix Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Resverlogix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
